Barton will use the Proteus medication adherence platform, which includes Proteus’ FDA-cleared ingestible sensor, for patients with uncontrolled and co-morbid hypertension. Implementation for other chronic conditions will follow if the first use case goes well, reported MobiHealthNews.
Proteus says this is the first time its technology has been implemented outside of a clinical trial setting in the US.
“Patients struggle with medication adherence for various reasons. When a non-adherent patient is not seeing results and the physician believes a patient is taking a medication, this may lead to unnecessary changes in treatment which can be costly for the patient and the health system,” CEO of Barton Health, Dr Clint Purvance, said in a statement.
“This new product offering provides a data-driven communication channel between the medical provider and the patient that empowers the patient to take the appropriate dose of medication and better understand the importance of daily activity levels and other lifestyle changes,” continued Dr Purvance.
Barton’s specialty pharmacy services will co-encapsulate the grain-of-sand-sized sensor with select generic medications for hypertension and comorbidities.
The sensor is activated automatically when it is broken down in the stomach and transmits the signal to a receiver on an adhesive patch worn by the patient. The patch then transmits data like heart rate, activity, rest and the time the pill was taken to an app on the patient’s mobile device. The patient can then share the data with their physician, where it will appear on a web-based dashboard app. The app also provides support and insight to the patient.
“Patients are seeking easier ways to engage in their own care; healthcare providers are looking to more effectively manage chronic conditions,” said CEO of Proteus, Andrew Thompson.
“Barton is among a group of pioneering health systems addressing these opportunities head on by adding digital health solutions that extend their physical footprint, laying the groundwork for a durable population health strategy,” added Thompson.
According to Forbes, both Thompson and Purvance firmly believe that within the next decade, digital medicines will become commonplace in our approach for management of chronic disease states, helping physicians to more effectively engage patients to participate in their ongoing care.